inVentiv Health acquires Catalina Health
November 6, 2013Medical Communications Adheris, catalina, inVentiv Health
Consulting and services company inVentiv Health has acquired a subsidiary of Catalina (Catalina Health) and joined it onto its own …
ImmunoGen stops cancer trial
November 6, 2013Research and Development, Sales and Marketing Cancer, IMGN901, Immunogen, Roche
Roche subsidiary ImmunoGen has abandoned a Phase II trial into small-cell lung cancer (SCLC) after deciding that it was not …
Profil Institute hires former Amylin chief executive
November 6, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amylin, profil institute
Clinical research firm Profil Institute has appointed former Amylin chief executive Dan Bradbury to its Board of directors. “Dan Bradbury …
UK is the go-to place for developing medicines
November 5, 2013Research and Development, Sales and Marketing BIA, Cell Medica, ReNeuron, UK
The BioIndustry Association (BIA) has said that the UK is clearly the must-go-to location for regenerative medicine research and development. …
J&J hit with $2.2 billion fine
November 5, 2013Sales and Marketing J&J, JJ, Janssen, Risperdal, antipsychotic, fine
Johnson & Johnson has admitted promoting its big-selling antipsychotic drug Risperdal off-label, costing the firm $2.2 billion in fines. The …
BMS files oral hep C treatment
November 5, 2013Sales and Marketing BMS, HCV, dvc, hep C
Bristol-Myers Squibb has filed its investigational hepatitis C treatment – the first oral regime without interferon or ribavirin – with …
Astellas poaches comms head from Lilly
November 5, 2013Astellas has hired Jeffrey Winton from Eli Lilly to be its senior vice president and chief communications officer.Winton who will …
GSK ‘may not face corporate charges’
November 5, 2013Medical Communications, Sales and Marketing China, GSK, bribery
GlaxoSmithKline is unlikely to face a company-wide charge for corruption following investigations by authorities in China according to reports. The …
GSK: no Votrient Code breaches
November 4, 2013Medical Communications, Sales and Marketing GSK, PMCPA, Pfizer
Obamacare: health reform’s tough start
November 1, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Medicare, Obama, Obamacare, US, affordable care act
On Tuesday 1 October, three years after it was passed, the Patient Protection and Affordable Care Act came into force …
Ariad cancer drug pulled amid safety fears
November 1, 2013Sales and Marketing Ariad, FDA, iclusig, leukaemia
Ariad Pharmaceuticals has been forced by the FDA to suspend sales of its blood cancer drug Iclusig given the high …
More changes at the top as AstraZeneca profits slip
November 1, 2013Sales and Marketing AstraZeneca, Crestor, Q3, profits
AstraZeneca’s third quarter revenues and profits fell below analysts’ expectations yesterday, but mitigated the news with the appointment of a …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
